Showing 5991-6000 of 7243 results for "".
- AIM at Melanoma Opens Melanoma Tissue Bank in the UShttps://practicaldermatology.com/news/aim-at-melanoma-opens-melanoma-tissue-bank-in-the-us/2459991/AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six global locations of the consortium. These six institutions
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Nextech Partners with RxPhoto for Integrated Image Managementhttps://practicaldermatology.com/news/nextech-partners-with-rxphoto-for-integrated-image-management/2459958/Nextech Systems has launched a new partnership with RxPhoto, a collaborative medical imagery solution. This partnership integrates RxPhoto’s patient photograph
- CoolSculpting and Sonja Morgan Partner to Talk Bikini Denialhttps://practicaldermatology.com/news/coolsculpting-and-sonja-morgan-partner-to-talk-bikini-denial/2459963/Star of Bravo's "The Real Housewives of New York City" Sonja Morgan is opening up about her ‘Bikini Denial’ as part of her partnership with CoolSculpting. Bikini Denial is the feeling that many woman get when realizing that swimsuit season has snuck up on her and
- More Positive Results Seen with Endo's Injectable Cellulite Treatmenthttps://practicaldermatology.com/news/more-positive-results-for-endos-injectable-cellulite-treatment/2459965/Endo International plc’s injectable cellulite treatment collagenase clostridium histolyticum ("CCH") showed a clinically meaningful and statistically significant improvement compared to placebo for all primary and secondary endpoints in a Phase 2
- AAD Announces 2019 Election Resultshttps://practicaldermatology.com/news/aad-announces-2019-election-results/2459967/The votes have been counted in the 2019 AAD Election, and the following candidates will take office at the conclusion of the 2020 Annual Meeting in Denver, Colorado on March 24, 2020.
- Pilot Study: Regular Moisturization May Cut Dementia Riskhttps://practicaldermatology.com/news/pilot-study-regular-moisturization-may-cut-dementia-risk/2459971/Inflamed skin in older adults may contribute to a wide range of age-related conditions including heart disease and Alzheimer’s disease, but regular moisturization may cool the inflammation and lower disease risk in the process, according to a pilot study. In the study, 33 adults age
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription